Drug Trial Radar · NCT07709598
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Oct 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a multiple-center, randomized, double-blind, placebo- and active-controlled parallel-group Phase II/III clinical trial, to evaluate the efficacy and safety of HL-1186 Tablets for Postoperative Analgesia in Abdominal Surgery.
Conditions
- Postoperative Pain
Interventions
HL-1186Drug
HL-1186 tablet for oral administration.
HL-1186 placeboDrug
HL-1186 placebo tablet for oral administration.
Oxycodone-AcetaminophenDrug
Oxycodone-Acetaminophen for oral adminstration.
Oxycodone-Acetaminophen Matching PlaceboDrug
Oxycodone-Acetaminophen Matching Placebo for oral adminstration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SPID48Time frame: 0 to 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.